Articles
Age-related Macular Degeneration Market Analysis, Size and Demand, 2022
by Vijay K. Web MarketingThe global age-related macular degeneration market was valued at $5,335.7 million in 2015, and it is expected to grow at a CAGR of 7.6% during 2016 – 2022. Among the various types, the wet AMD segment is expected to witness the faster growth compared to dry AMD segment, during the forecast period. The global age-related macular degeneration market is growing at a significant rate, due to increasing healthcare cost, and increasing prevalence lifestyle associated diseases, such as obesity and hypertension. In addition, the growing geriatric population, increasing prevalence of AMD and increasing pipeline drugs for AMD are also driving the growth of the global age-related macular degeneration market.
Explore Report with
Detailed TOC at: https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market
Age-related macular degeneration (AMD) is an
acquired retinal disorder indicated by fundus changes. It is one of the most
common forms of visual impairment in the geriatric population. It is a
deterioration or degeneration of macular, leading to vision loss among people
aged 60 years and above. The macula is a small
part of retina responsible for sharpness and central vision.
Some
of the key companies operating in the global age-related macular degeneration
market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron
Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech
Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences,
Inc.
Sponsor Ads
About Vijay K. 
Web Marketing
211 connections, 3 recommendations, 864 honor points.Joined APSense since, May 17th, 2016, From New York, United States.
Created on Dec 13th 2017 14:34. Viewed 432 times.
